Building the Next Generation of MedTech Leaders
Exploring One Six 8 Ventures’ Portfolio
One Six 8 Ventures focuses on funding next-generation MedTech companies through a precision-based approach designed to minimize risk and unlock superior returns. We target exceptional deals in Canada while identifying unique global opportunities that align with our investment thesis.
Our team leverages deep scientific experience and operational expertise to source opportunities from a pipeline of 600 annual deals, often partnering alongside institutional co-investors. This selective approach allows us to identify companies with strong technical foundations, clear paths to commercialization, and significant potential for strategic acquisition.
We seek entrepreneurs who are developing solutions that address urgent healthcare needs, demonstrate technological differentiation, and can scale to meet global demand. Our portfolio reflects this disciplined focus on companies positioned to become category leaders in their respective fields.
Current Portfolio Companies
-
Pulse Medica, a Canadian company, develops a non-invasive, image-guided laser platform to screen and treat vitreoretinal disease. Their platform represents the first safe and effective system for this purpose, starting with vitreous opacities, commonly known as eye floaters.
The company utilizes a next-generation femtosecond laser that enables precise treatment and imaging capabilities. This technology addresses a widespread condition that affects quality of life for millions of people globally, yet has historically lacked effective treatment options. Pulse Medica's approach combines advanced imaging with targeted laser therapy to provide a solution that meets both clinical efficacy and safety standards.
The platform's design reflects years of research and development in laser technology, optical imaging, and ophthalmology. As the company advances through clinical validation and regulatory pathways, the technology holds potential to establish a new standard of care for vitreoretinal conditions.
-
Fluid Biomed, also based in Canada, has designed a hybrid polymer-metal flow-diverting stent for treating brain aneurysms. The company's team of neurosurgeons, scientists, and engineers created this device to address critical limitations in existing neurovascular treatment options.
The device functions by diverting blood flow away from the aneurysm, allowing the blood vessel to heal naturally. A key innovation lies in its bioabsorbable design, which provides the necessary structural support during the healing process while minimizing long-term foreign material presence in the body.
Another significant advantage involves the device's compatibility with standard imaging modalities. The hybrid construction minimizes interference with CT and MRI scans, enabling physicians to monitor patient progress and assess treatment outcomes more effectively than with conventional metal stents. This feature addresses a longstanding challenge in neurovascular intervention where imaging artifacts can obscure critical diagnostic information.
The development of this technology draws on expertise across multiple disciplines, combining insights from clinical practice with advanced materials science and medical device engineering.
Our Unique MedTech Investment Approach
Our portfolio strategy centres on companies that demonstrate technical excellence, address substantial market opportunities, and maintain clear pathways to strategic value creation. We seek entrepreneurs who combine deep domain expertise with the ambition to build companies that transform healthcare delivery.
Through active partnership and strategic guidance, we work alongside our portfolio companies to accelerate development timelines, establish connections with strategic acquirers, and navigate the complex regulatory and commercial landscapes inherent to MedTech innovation. Our team's operational experience allows us to provide relevant support at each stage of company growth.
Partner with Experience
Meet our team to learn about the operators and executives guiding our portfolio companies, or get in touch to discuss potential investment opportunities.